Telmisartan, an angiotensin II type-1 receptor blocker, improved insulin resistance in a schizophrenic patient treated with olanzapine: A case report

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 1, 2008, Pages 308-310

  Yamashita, Hakuei ^a,b   Yoda, Hiroo ^a,b   Maruki, Taeko ^a   Toyoshima, Ryoichi ^b  

^a Department of Psychiatry   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; HALOPERIDOL; INSULIN; OLANZAPINE; TELMISARTAN;

ADULT; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BODY MASS; BODY WEIGHT; CASE REPORT; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; LABORATORY TEST; LETTER; MONOTHERAPY; ORAL GLUCOSE TOLERANCE TEST; PARANOIA; PHYSICAL EXAMINATION; RESTLESSNESS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIPSYCHOTIC AGENTS; BENZIMIDAZOLES; BENZOATES; BENZODIAZEPINES; FEMALE; HUMANS; INSULIN RESISTANCE; SCHIZOPHRENIA;

EID: 38349061844     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.08.022     Document Type: Letter

References (15)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). Forth ed (1994), American Psychiatric Association Publications Division, Washington DC
2. Benndorf R.A., Rudolph T., Appel D., Schwedhelm E., Maas R., Schulz F., et al. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 55 (2006) 1159-1164
3. Callagham J.T., Bergstrom R.F., Ptak L.R., and Beasley C.M. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37 3 (1999) 177-193
4. Cavazzoni P., Tanaka Y., Roychowdhury S.M., Breier A., and Allison D.B. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 13 (2003) 81-85
5. Ebner T., Heinzel G., Prox A., Beschke K., and Wachsmuyh H. Disposition and chemical stability of telmisartan 1-o-acylglucuronide. Drug Metab Dispos 27 10 (1999) 1143-1149
6. Fogari R., Derosa G., Zoppi A., Rinaldi A., Lazzari P., Fogari E., et al. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res 28 3 (2005) 209-214
7. Fukushima M., Suzuki H., and Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 66 Suppl 1 (2004) S37-S43
8. Furuhashi M., Ura N., Higashiura K., Murakami H., Tanaka M., Moniwa N., et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42 1 (2003) 76-81
9. Hara K., Horikoshi M., Yamauchi T., Yago H., Miyazaki O., Ebinuma H., et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29 6 (2006) 1357-1362
10. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 12 (2005) 1209-1223 [22]
11. Lu M.L., Lane H.Y., Lin S.K., Chen K.P., and Chang W.H. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 65 6 (2004) 766-771
12. Melkersson K.I., and Dahl M.L. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology 170 2 (2003) 157-166
13. Nagel J.M., Tietz A.B., Goke B., and Parhofer K.G. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism 55 9 (2006) 1149-1154
14. Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59 4 (2002) 337-345
15. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7 8 (2001) 941-946